Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-17T06:43:34.586Z Has data issue: false hasContentIssue false
  • English
  • Français

A Retrospective Study of Multiple Sclerosis in Siriraj Hospital, Bankok, Thailand

Published online by Cambridge University Press:  02 December 2014

Sasitorn Siritho  and
Naraporn Prayoonwiwat
Sasitorn Siritho
Affiliation:
Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Prannok Road, Bangkok, Thailand
Naraporn Prayoonwiwat
Affiliation:
Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Prannok Road, Bangkok, Thailand
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To determine the demographic and clinical data of Thai multiple sclerosis (MS) patients.

Methods:

A retrospective study of 72 patients attending the MS clinic at Siriraj Hospital, Mahidol University, Thailand between January 1997 and June 2004.

Results:

Fifty-eight patients (81%) were classified as clinically definite MS, 5 (7%) as Devic's syndrome, and 9 (13%) as possible MS. There were 62 females (86%) and 10 males (14%). Age at onset was 33 ± 12 years with a mean relapse rate of 1.2 ± 1.0 attacks per annum. None had a family history of MS. Visual impairment (53%) was the most common manifestation. Only 16% had classic (western) form of MS. Positive oligoclonal bands were found in 21%, visual evoked potentials with a typical delayed latency in 28%. MRI brain lesions compatible with McDonald's criteria were seen in only 24%, and spinal MRI brain longer than 2 vertebral bodies in 62%. The mean Kurtzke's Expanded Disability Status Scale (EDSS) was 3.0.

Conclusion:

Thai MS patients had much more female occurrence, no family history, common optico-spinal form, long spinal MRI lesions and low positive CSF oligoclonal bands.

Type
Exchange Article
Information
Canadian Journal of Neurological Sciences , Volume 34 , Issue 1 , February 2007 , pp. 99 - 104
Copyright
Copyright © The Canadian Journal of Neurological 2007

References

1. Compston, A, Coles, A. Multiple sclerosis. Lancet. 2002; 359: 1221–31.Google Scholar
2. Noseworthy, JH, Lucchinetti, C, Rodriguez, M, Weinshenker, BG. Multiple sclerosis. N Eng J Med. 2000; 343: 938–52.CrossRefGoogle ScholarPubMed
3. Weinshenker, BG. Natural history of multiple sclerosis. Ann Neurol. 1994; 36(Suppl): S6–11.Google Scholar
4. Lublin, FD, Reigngold, SC. Defining the clinical course of multiple sclerosis: results of international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46: 907–11.CrossRefGoogle ScholarPubMed
5. Shibasaki, H, McDonald, WI, Kuroiwa, Y. Racial modification of clinical picture of multiple sclerosis. J Neurol Sci. 1981; 49: 253–71.CrossRefGoogle ScholarPubMed
6. Li, PCK, Ong, B, Lee, KH, Prayoonwiwat, N, Tan, CT, Tsai, CP. Asia Pacific multiple sclerosis consensus. Neurol J Southeast Asia. 1999; 4: 89–90.Google Scholar
7. Kira, J, Kanai, T, Nishimura, Y, et al. Western versus Asian types of multple sclerosis: Immunogenetically and clinically distinct disorders. Ann Neurol. 1996; 40: 569–74.Google Scholar
8. Kuroiwa, Y, Hung, TP, Landsborough, D, Park, CS, Signhal, BS. Multiple sclerosis in Asia. Neurology. 1997; 27: 188–92.Google Scholar
9. Tan, CT, Chong, HT. Devic’s disease and multiple sclerosis in Asia. Neurol J Southeast Asia. 1999; 4: 57–9.Google Scholar
10. Chong, HT, Li, PCK, Ong, B, Lee, KH, Tsai, CP, Singhal, BS, Prayoonwiwat, N, Tan, CT. Severe spinal cord involvement is a universal feature of Asians with multiple sclerosis: A joint Asian study. Neurol J Southeast Asia. 2002; 7: 35–40.Google Scholar
11. Barkhof, F, Filippi, M, Miller, DH. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite MS. Brain. 1997; 120: 2059–69.CrossRefGoogle Scholar
12. McDonald, WI, Alistair, C. Recommended diagnostic criteria for multiple sclerosis Guideline from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001; 50: 121–7.Google Scholar
13. Poser, CM, Paty, PW, Scheinberg, L. New diagnostic criteria for multiple sclerosis: guideline for research protocols. Ann Neurol. 1983; 13: 227–31.Google Scholar
14. Fukazawa, T, Kikuchi, S, Niino, M, Yabe, I, Hamada, T, Tashiro, K. Multiphasic demyelinating disorder with acute transverse myelitis in Japanese. J Neurol. 2003; 250: 624–6.Google Scholar
15. Kim, KK. Idiopathic recurrent transverse myelitis. Arch Neurol. 2003; 60: 1290–4.Google Scholar
16. Kuroiwa, Y. Neuromyelitis optica (Devic’s disease, Devic’s syndrome). In: Koetsier, JC, ed: Handbook of Clinical Neurology Vol 3 (47): Demyelinating disease. Elsevier Science Publishers B.V. 1985:397–408.Google Scholar
17. Kurtzke, JE. Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS). Neurology. 1983; 33: 1444–52.Google Scholar
18. Vejjajiva, A. Some aspects of multiple sclerosis in Thai patients. In Kuroiwa, Y, Kurland, LT, eds: Multiple Sclerosis East and West. Fukuoka: Kyushu University Press. 1982: 117–21.Google Scholar
19. Jitpimolmard, S, Vejjajiva, A. Clinical features and clinical course of multiple sclerosis in Thai patients: a report of 50 cases. J Med Assoc Thai. 1994; 77: 239–43.Google ScholarPubMed
20. Vejjajiva, A. Multiple sclerosis in Thailand. Neurol J Southeast Asia. 1997; 2: 7–10.Google Scholar
21. Baun, HM, Rothschild, BB. The incidence and prevalence and the risk of relapse in multiple sclerosis. N Eng J Med. 2001; 344: 319–26.Google Scholar
22. Kira, J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003; 2: 117–27.Google Scholar
23. Misu, T, Fujihara, K, Nakashima, I. Pure optic-spinal form of multiple sclerosis in Japan. Brain. 2002; 125: 2460–8.CrossRefGoogle ScholarPubMed
24. Optic Neuritis Study Group: Visual function 5 years after optic neuritis. experience of the optic neuritis treatment trial. Arch Opthalmol. 1997; 115: 1545–52.CrossRefGoogle Scholar
25. Optic Neuritis Study Group: The 5 years risk of MS after optic neuritis. experience of the optic neuritis treatment trial. Neurology. 1997; 49: 1404–13.Google Scholar
26. Weinshenker, BG. Neuromyelitis optica: What it is and what it might be. Lancet. 2003; 361: 889–90.Google Scholar
27. Shibasaki, H, Kuroiwa, Y. Painful tonic seizure in multiple sclerosis. Arch Neurol. 1974; 30: 47–51.CrossRefGoogle ScholarPubMed
28. Francis, GS, Evans, AC, Arnold, DL. Neuroimaging in multiple sclerosis. Neurol Clin. 1995; 13: 147–71.Google Scholar
29. Tintoreé, M, Rovira, A, Martyénez, MJ, et al. Isolated demyelinating syndromes: Comparison of different imaging criteria to predict conversion to clinically definite MS. Am J Radiology. 2000; 21: 702–6.Google Scholar
30. Chong, HT, Ramli, N, Lee, KH, et al. Magnetic resonance imaging of Asians with multiple sclerosis was similar to that of the West. Neurol Asia. 2004; 9: 47–53.Google Scholar
31. Nakashima, I, Fujihara, K, Misu, T, Fujimori, J, Sato, S. A comparative study of Japanese multiple sclerosis patients with and without oligoclonal IgG bands. Mult Scler. 2002; 8: 459–62.Google Scholar
32. Jacobs, LD, Cookfair, DL, Rudick, RA. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39: 285–94.CrossRefGoogle Scholar
33. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: Long term efficacy of interferon beta-1a in relapsing remitting multiple sclerosis. Neurology. 2001; 56: 1628–36.Google Scholar
34. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet. 1998; 352: 1498–504.CrossRefGoogle Scholar
35. Goodin, DS, Frohman, EM, Garmany, GP, et al. Disease modifying therapies in multiple sclerosis. Neurology. 2002; 58: 169–78.Google ScholarPubMed
36. Saida, T, Tashiro, K, Itoyama, Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology. 2005; 64: 621–30.Google Scholar
37. Ashtari, F, Chitsaz, A, Khorvash, F, Shaygannejad, V. Efficacy of interferon beta-1a in Iranian multiple sclerosis. Neurol Asia. 2005; 10: 109–12.Google Scholar